Is Sotorasib available in Hainan?

Sotorasib (Sotorasib) is a new type of targeted treatment for lung cancer. It is a treatment option for patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). The KRAS G12C mutation is a common cancer-associated mutation, particularly in lung cancer, and sotorasiib is the first approved treatment to target this specific mutation.

The original drug of sotolasibu has not yet been launched in China, so patients cannot purchase it domestically. Therefore, Hainan cannot purchase it. Sotolasibu needs to be purchased through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

This drug blocks the growth and spread of cancer cells by specifically inhibiting the activity of the KRAS G12C mutated protein. It is a small molecule inhibitor that binds to the KRAS G12C protein and prevents its binding to GTP, thus interfering with the signaling pathway and causing cancer cells to lose signals for survival and proliferation.

The development of sotorasiib is based on an in-depth understanding of the molecular biology of lung cancer, especially the study ofKRAS mutations. Clinical trial results show that this drug exhibits significant anti-tumor activity in some KRAS G12C mutation-positive NSCLC patients, providing a glimmer of hope for this urgent treatment problem.

Although sotoracib has made significant progress in the treatment of KRAS G12C mutation-positive non-small cell lung cancer, it still needs to be verified in larger clinical practice. In addition, as further research and clinical experience accumulates, a deeper understanding of its long-term efficacy, safety, and potential applications in other cancer types will be required.